Epigral (EPIGRAL) Research Report — As of July 30, 2026

1. Catalyst & News Analysis

On July 30, 2026, Epigral conducted an investor meet detailing its Q1 FY27 performance and strategic expansion plans. Note that the core expansion announcement—a ₹600 Cr capex for a 125,000 TPA Epoxy Resin facility and Multipurpose Plant (MPP)—was initially disclosed on July 27, 2026. Therefore, this analyst call update is evaluated as already priced in in terms of initial announcement shock, but provides critical operational roadmap details.

Key strategic elements of the announcement: - Forward Integration: The 125k TPA Epoxy Resin unit will consume 50% of Epigral's internal Epichlorohydrin (ECH) production, converting an intermediate into a high-value downstream product. - Peak Top-Line Guidance: Chlorotoluene and MPP value chains are projected to contribute ₹700-800 Cr annually at peak utilization. - Ongoing Expansion Tracking: CPVC capacity doubling (75k to 150k TPA) and ECH capacity doubling (50k to 100k TPA) remain on track for H1 FY27 completion.

2. Ramp-Aware Execution & Financial Impact Math

• TTM Base Revenue: ₹2,527 Cr | TTM PAT: ₹332 Cr | TTM EPS: ₹76.96
• Capex Size: ₹600 Cr (23.7% of TTM revenue).
• Execution Timeline: Project completion targeted over 2 to 2.5 years (H2 FY28).

Revenue Ramp Profile: - Year 1 (FY27): Revenue growth will be led by ongoing CPVC and ECH expansions ramping up in H2 FY27. Estimated Year 1 revenue uplift: 12% (~₹300 Cr), bringing FY27 revenue to ~₹2,820 Cr. - Steady State (FY28/29): Full commercialization of Chlorotoluene, MPP, and Epoxy Resin lines will add ~₹900-1,000 Cr in gross revenue (35% uplift over TTM base).

Earnings Impact: - At steady state, increased specialty mix (targeting 70% share) is projected to lift consolidated OPM from ~22.4% toward 25-26%. - Assuming a 25% EBITDA margin on ₹3,500 Cr steady-state revenue yields ₹875 Cr EBITDA. - After accounting for depreciation, interest on ₹600 Cr debt/internal accruals, and 25% tax rate, estimated steady-state PAT reaches ₹430-450 Cr (representing a ~30% EPS uplift over normalized TTM PAT).

3. Fundamental Quality & Governance Evaluation

• Minervini SEPA Grade: B (Strong growth trajectory, transitioning from commodity chlor-alkali to specialty chemicals).
• Quality Gate: Passed. ROCE stands at 15.0%, backed by low leverage (D/E 0.26x) and promoter shareholding of 68.8%.
• Governance: Clean report with no auditor qualifications or pledge concerns.

4. Valuation Context & Scenarios (24-36 Month Horizon)

Epigral trades at 14.6x trailing P/E, presenting a significant discount to specialty chemical peers (median P/E of 44.8x). This valuation discount reflects historical market exposure to cyclical caustic soda realizations. As downstream specialty mix rises to 70%, re-rating headroom is substantial.

• Base Case (+45% upside): Steady-state EPS of ₹100; exit P/E multiple re-rates moderately to 16-18x, yielding a target price around ₹1,635.
• Bull Case (+85% upside): Rapid ramp-up of Epoxy and CPVC lines, strong realization spreads; EPS reaches ₹115 with exit multiple expanding to 22x (target price ₹2,085).
• Bear Case (-20% downside): Sharp drop in caustic soda prices offsetting specialty gains or delays in commissioning; EPS drops to ₹65, valuation compresses to 14x (target price ~₹900).

5. Multibagger Verdict Rationale

Epigral is classified as a POSSIBLE multibagger candidate (Score: 72/100). The strategic direction—moving down the value chain into import-substitution products like ECH, CPVC, and Epoxy Resin—is structural and value-accretive. However, execution of ₹600 Cr capex over the next 24-36 months alongside cyclical commodity risks keeps the verdict at POSSIBLE rather than STRONG_CANDIDATE.

Investment Analysis: Epigral Limited (EPIGRAL)

Date: July 27, 2026
Current Price: ₹1,202.30 | Market Cap: ₹5,187 Cr
Event Evaluated: ₹600 Cr Capex announcement for 1,25,000 TPA Epoxy Resin facility and Multi-Purpose Plant (MPP).

1. Catalyst Evaluation & Ramp-Aware Math

Epigral announced a strategic expansion of ₹600 Cr to enter the Epoxy Resin segment (1.25 Lakh TPA capacity) and build a Multi-Purpose Plant at Dahej, target completion H2 FY2028.

• Integration Rationale: Epigral is expanding ECH capacity to 100,000 TPA. Epichlorohydrin (ECH) is the key primary raw material for Epoxy Resins. Producing Epoxy Resin internally represents high-margin downstream integration.
• Capital Intensity & Execution Timeline: Chemical capex takes ~18–24 months to construct and commission, followed by 12–18 months of commercial ramp-up. Completion is targeted for H2 FY2028 (ending March 2028).
• Year-1 Revenue Uplift (FY2027): 0.0% (facility under construction).
• Steady-State Revenue Uplift (FY2029–30): Assuming 1.2x asset turnover on ₹600 Cr capex, the plant will generate ~₹720–750 Cr in annual incremental revenue (+29.7% over TTM Revenue of ₹2,527 Cr).
• Steady-State EPS Impact: At an expected operating margin of 20% and net margin of ~13%, annual incremental PAT is estimated at ~₹95 Cr. Relative to normalized annual PAT of ~₹250 Cr (adjusting for one-off tax benefits), this represents a +32.5% EPS uplift at full utilization.

2. Quality Gate & Fundamentals

• ROCE & Balance Sheet: ROCE stands at 15.0% with a prudent Debt/Equity ratio of 0.26 (Debt: ₹572 Cr, Net Worth: ₹2,221 Cr). Promoter holding is stable at 68.8%.
• Growth Strategy Shift: Epigral is actively pivoting from a commodity Chlor-Alkali producer (susceptible to caustic soda pricing cycles) to a specialty chemical player (targeting 70% revenue share from CPVC, ECH, Chlorotoluene, and Epoxy Resins).
• Valuation Advantage: Trailing P/E of 15.6x offers significant safety margin compared to the specialty chemical peer median of 45.4x.

3. Scenario Analysis & Calibrated Returns (24-36 Month Horizon)

• Bull Case (+110% / Target Price: ₹2,525): Seamless execution of CPVC, ECH, and Epoxy Resin projects; Chlor-Alkali realizations rebound; P/E re-rates from 15.6x to 28x as specialty mix exceeds 60%.
• Base Case (+55% / Target Price: ₹1,860): On-time commissioning in H2 FY28; gradual volume absorption; P/E re-rates moderately to 20x on higher structural ROCE.
• Bear Case (-25% / Target Price: ₹900): Execution delays beyond FY28; sustained global weakness in Chlor-Alkali prices compressing cash flows; margin contraction under fixed overheads.

4. Final Verdict

Epigral is executing a textbook multi-year downstream integration play, using its captive chlorine and glycerol-based ECH to move into higher-margin derivatives like Epoxy Resins. While the catalyst has an 18-24 month gestation period before revenue recognition, the current depressed valuation (15.6x P/E) creates a compelling risk-reward profile for long-term compounder potential.